In vivo studies confirmed that the candidate drugs targeting CD74, doxorubicin and milatuzumab, have a tendency to inhibit EMT. IGHG1+ MEC collaborate with myCAF to shape a pro-metastatic microenvironment, with the MIF-CD74/APP-CD74 interaction network serving as a driver of NSCLC brain metastasis. CD74-targeting therapies show promising clinical potential.
14 days ago
Journal
|
CD74 (CD74 Molecule) • IGHG1 (Immunoglobulin Heavy Constant Gamma 1)
Crucially, Milatuzumab, a CD74-targeting antibody, reversed MIF-induced TAM immunosuppression in vitro. Our research provides a comprehensive map of GC-TAM heterogeneity; reveals that the MIF-CD74 axis is a key driver of TAM-mediated immune suppression; and proposes that CD74 blockade is a new therapeutic strategy for GC.